
亚太药物基因组学市场预测至 2028 年 - COVID-19 影响和区域技术分析(PCR、测序、微阵列、凝胶电泳、质谱等)、应用(药物发现、肿瘤学、神经病学和精神病学、疼痛管理、心血管疾病)等)和最终用户(医院和诊所、生物制药公司、CRO 和 CDMO 等)
No. of Pages: 170 | Report Code: TIPRE00028847 | Category: Life Sciences
No. of Pages: 170 | Report Code: TIPRE00028847 | Category: Life Sciences
推动市场增长的关键因素是对第三代测序的需求不断增加以及药物基因组研究活动资金的增加。然而,熟练专业人员的缺乏预计将限制预测期内的市场增长。
更新更好的 DNA 测序技术的发展导致了千倍以上的增长。自人类基因组计划启动以来,基因组测序成本下降。三代测序是在二代测序上市后进行的。过去几年,基因组测序技术彻底改变了遗传疾病的突变检测。第三代测序(TGS)凭借单分子和实时测序技术,深入了解了更多遗传疾病。
Pacific Biosciences 开发了名为“单分子”的新技术实时测序 (SMRT)。 SMRT 非常高效,并且使用较少的昂贵化学品。其高灵敏度使科学家能够有效观察 DNA 聚合酶并观察其形成 DNA 链。
第三代测序 (TGS) 技术需求的增长归因于辐射剂量管理领域利润丰厚的增长率。随着 TGS 的出现,基因组测序已成为研究基因组变异的更快、更可靠的方法。 SMRT技术使科学家能够对已测序的基因组进行重新测序,以获得更高的准确性。使用 SMRT 技术对大肠杆菌进行测序,准确率高达 99.99%。
第三代远程 DNA 测序和作图技术正在实现高质量的基因组测序。与第二代测序产生超过数百个碱基对的短读段不同,第三代单分子技术可生成超过 10,000 bp 的读段或映射超过 100,000 bp 的分子。
在至少 14 个国家总计超过 40 亿美元的政府投资的支持下,药物基因组学正在迅速过渡到临床实践和医疗保健系统中的实施。这些国家基因组医学计划在现实生活条件下推动变革,同时解决实施障碍并收集证据以促进更广泛的采用。
2020 年 4 月,MedGenome—总部位于班加罗尔的基因诊断、研究和数据公司——宣布在由全球影响力投资公司 LeapFrog Investments 领投的新一轮融资中筹集了 5500 万美元(约合 41.9 亿印度卢比)。此外,MedGenome 声称已在印度的遗传诊断和研究合作伙伴关系中建立了最大的南亚遗传变异数据库。迄今为止,它已完成了超过 200,000 项基因组测试,并从印度各地 550 多家医院和 6,000 名临床医生获取了样本。 因此,制造商和政府在基因组学领域的持续资助正在推动药物基因组学市场的发展。< /span>
Strategic insights for Asia Pacific Pharmacogenomics involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
Report Attribute | Details |
---|---|
Market size in 2021 | US$ 1,148.36 Million |
Market Size by 2028 | US$ 2,679.64 Million |
Global CAGR (2021 - 2028) | 11.2% |
Historical Data | 2019-2020 |
Forecast period | 2022-2028 |
Segments Covered |
By 技术
|
Regions and Countries Covered | 亚太地区
|
Market leaders and key company profiles |
The regional scope of Asia Pacific Pharmacogenomics refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Asia Pacific Pharmacogenomics Market is valued at US$ 1,148.36 Million in 2021, it is projected to reach US$ 2,679.64 Million by 2028.
As per our report Asia Pacific Pharmacogenomics Market, the market size is valued at US$ 1,148.36 Million in 2021, projecting it to reach US$ 2,679.64 Million by 2028. This translates to a CAGR of approximately 11.2% during the forecast period.
The Asia Pacific Pharmacogenomics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Pharmacogenomics Market report:
The Asia Pacific Pharmacogenomics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Pharmacogenomics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Pharmacogenomics Market value chain can benefit from the information contained in a comprehensive market report.